← Eichor
Study identifier: NCT05738980 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3

Condition: Hepatocellular Carcinoma  ·  Sponsor: Beijing Hospital

PhaseNA
Planned participants88
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

To compare the safety and efficacy of unmodified RAK cells and anti-TIM-3 blocked autologous RAK cells in preventing postoperative recurrence of HCC by postoperative TACE therapy combined with immune cell therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Caixia Liu, master  ·  010-85133662  ·  liucxmm@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Hospital Center of BiotherapyBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05738980